Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBITDA (2022 - 2025)

Praxis Precision Medicines has reported EBITDA over the past 4 years, most recently at -$97.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$97.0 million for Q4 2025, down 51.74% from a year ago — trailing twelve months through Dec 2025 was -$326.2 million (down 62.96% YoY), and the annual figure for FY2025 was -$326.2 million, down 62.96%.
  • EBITDA for Q4 2025 was -$97.0 million at Praxis Precision Medicines, down from -$78.4 million in the prior quarter.
  • Over the last five years, EBITDA for PRAX hit a ceiling of -$25.5 million in Q3 2023 and a floor of -$97.0 million in Q4 2025.
  • Median EBITDA over the past 4 years was -$50.6 million (2022), compared with a mean of -$54.2 million.
  • Biggest five-year swings in EBITDA: surged 44.67% in 2023 and later crashed 130.01% in 2024.
  • Praxis Precision Medicines' EBITDA stood at -$41.5 million in 2022, then skyrocketed by 32.92% to -$27.8 million in 2023, then crashed by 130.01% to -$64.0 million in 2024, then tumbled by 51.74% to -$97.0 million in 2025.
  • The last three reported values for EBITDA were -$97.0 million (Q4 2025), -$78.4 million (Q3 2025), and -$76.1 million (Q2 2025) per Business Quant data.